State Key Laboratory of Proteomics, Beijing Proteome Research Center, Beijing Institute of Radiation Medicine, No 33 Life Science Park Road, Beijing 102206, China.
BMC Cancer. 2010 Jul 6;10:356. doi: 10.1186/1471-2407-10-356.
Hepatocellular carcinoma (HCC) is one of the world's leading causes of death among cancer patients. It is important to find a new biomarker that diagnoses HCC and monitors its treatment. In our previous work, we screened a single-chain antibody (scFv) N14, which could specifically recognize human HepG2 HCC cells but not human non-cancerous liver LO2 cells. However, the antigen it recognized in the cells remained unknown.
Recombinant scFv N14 antibody was expressed as an active antibody. Using this antibody with a combination of immunological and proteomic approaches, we identified the antigen of scFv N14 antibody as the heterogeneous nuclear ribonucleoprotein A2/B1 (hnRNP A2/B1). The expression of hnRNP A2/B1 in HCC cells was then investigated by semi-quantitative RT-PCR and immunohistochemistry.
We found that the up-regulation of hnRNP A2/B1 was measured at both transcriptional and translational levels in rat HCC cells but not in rat hepatic cells. We also found that in various human hepatic tissues, hnRNP A2/B1 was highly expressed in both human hepatitis virus positive liver tissues and human HCC tissues but not in normal liver tissues. Interestingly, we observed that the localization of hnRNP A2/B1 in HCC cells was altered during the development of HCC. In human hepatitis virus infected tissues hnRNP A2/B1 resides exclusively in the nuclei of hepatocytes. However, when the HCC progressed from a well differentiated to a poorly differentiated stage, hnRNP A2/B1 was increasingly localized in the cytoplasm. In contrast, the HCC tissues with hnRNP A2/B1 highly expressed in the nucleus decreased.
This work is the first to show that hnRNP A2/B1 is the antigen specifically recognized by the scFv N14 antibody in HCC cells. The over-expression of hnRNP A2/B1 was confirmed in cultured human and rat HCC cell lines, human virus related hepatitis liver tissues and human HCC tissues. The increased localization of hnRNP A2/B1 in the cytoplasm of HCC cells was revealed during the dedifferentiation of hepatocellular carcinoma. Therefore, we suggest that the increased expression and cytoplasmic localization of hnRNP A2/B1 can be used as a diagnostic biomarker to assess the risk of human liver cancer.
肝细胞癌(HCC)是全球癌症患者死亡的主要原因之一。寻找新的生物标志物来诊断 HCC 并监测其治疗效果非常重要。在我们之前的工作中,我们筛选出了一种能够特异性识别人 HepG2 HCC 细胞但不识别人非癌性肝脏 LO2 细胞的单链抗体(scFv)N14。然而,该 scFv 识别的细胞内抗原仍不清楚。
表达了重组 scFv N14 抗体作为活性抗体。我们使用该抗体与免疫和蛋白质组学方法相结合,鉴定出 scFv N14 抗体的抗原为异质核核糖核蛋白 A2/B1(hnRNP A2/B1)。然后通过半定量 RT-PCR 和免疫组织化学检测 HCC 细胞中 hnRNP A2/B1 的表达。
我们发现,hnRNP A2/B1 的上调在大鼠 HCC 细胞中在转录和翻译水平上均有测量,但在大鼠肝细胞中没有。我们还发现,在各种人肝组织中,hnRNP A2/B1 在人乙型肝炎病毒阳性肝组织和人 HCC 组织中高度表达,但在正常肝组织中不表达。有趣的是,我们观察到 hnRNP A2/B1 在 HCC 细胞中的定位在 HCC 的发展过程中发生了改变。在乙型肝炎病毒感染的组织中,hnRNP A2/B1 仅存在于肝细胞的核内。然而,当 HCC 从高分化发展为低分化阶段时,hnRNP A2/B1 越来越定位于细胞质中。相反,hnRNP A2/B1 在核内高表达的 HCC 组织减少。
这项工作首次表明 hnRNP A2/B1 是 HCC 细胞中 scFv N14 抗体特异性识别的抗原。在培养的人和大鼠 HCC 细胞系、人病毒相关肝炎肝组织和人 HCC 组织中均证实了 hnRNP A2/B1 的过表达。在肝癌细胞的去分化过程中,hnRNP A2/B1 在细胞质中的定位增加。因此,我们建议 hnRNP A2/B1 的表达增加和细胞质定位可作为评估人类肝癌风险的诊断生物标志物。